Camp4 Therapeutics Corp (CAMP) SEC filings

CAMPNasdaqPharmaceutical PreparationsFiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026Score 6/3057% above fair value

$3.80−0.29 (-7.09%)

Close on Nov 13, 2026Market cap $238.46MP/E –Yield 0.00%

SEC filings

37 of Camp4 Therapeutics's most recent filings on SEC EDGAR

Document	Form	Period	Filed	Source
Quarterly report	10-Q	Sep 30, 2026	Nov 5, 2026	SEC EDGAR
Current report	8-K	Nov 5, 2026	Nov 5, 2026	SEC EDGAR
Current report	8-K	Sep 28, 2026	Sep 28, 2026	SEC EDGAR
Quarterly report	10-Q	Jun 30, 2026	Aug 13, 2026	SEC EDGAR
Current report	8-K	Aug 13, 2026	Aug 13, 2026	SEC EDGAR
Current report	8-K	Aug 3, 2026	Aug 4, 2026	SEC EDGAR
Current report	8-K	Jul 27, 2026	Jul 27, 2026	SEC EDGAR
Current report	8-K	Jun 10, 2026	Jun 12, 2026	SEC EDGAR
Current report	8-K	May 14, 2026	May 14, 2026	SEC EDGAR
Quarterly report	10-Q	Mar 31, 2026	May 7, 2026	SEC EDGAR
Current report	8-K	May 7, 2026	May 7, 2026	SEC EDGAR
Proxy statement	DEF 14A	Jun 10, 2026	Apr 23, 2026	SEC EDGAR
Current report	8-K	Mar 18, 2026	Mar 24, 2026	SEC EDGAR
Annual report	10-K	Dec 31, 2025	Mar 5, 2026	SEC EDGAR
Current report	8-K	Mar 5, 2026	Mar 5, 2026	SEC EDGAR
Current report	8-K	Jan 9, 2026	Jan 9, 2026	SEC EDGAR
Current report	8-K	Dec 22, 2025	Dec 23, 2025	SEC EDGAR
Current report	8-K	Dec 17, 2025	Dec 18, 2025	SEC EDGAR
Current report	8-K	Dec 18, 2025	Dec 18, 2025	SEC EDGAR
Quarterly report	10-Q	Sep 30, 2025	Nov 6, 2025	SEC EDGAR
Current report	8-K	Nov 6, 2025	Nov 6, 2025	SEC EDGAR
Current report	8-K	Oct 1, 2025	Oct 1, 2025	SEC EDGAR
Current report	8-K	Sep 9, 2025	Sep 10, 2025	SEC EDGAR
Quarterly report	10-Q	Jun 30, 2025	Aug 14, 2025	SEC EDGAR
Current report	8-K	Aug 14, 2025	Aug 14, 2025	SEC EDGAR
Current report	8-K	Jun 11, 2025	Jun 13, 2025	SEC EDGAR
Current report	8-K	May 16, 2025	May 16, 2025	SEC EDGAR
Quarterly report	10-Q	Mar 31, 2025	May 13, 2025	SEC EDGAR
Current report	8-K	May 13, 2025	May 13, 2025	SEC EDGAR
Proxy statement	DEF 14A	Jun 11, 2025	Apr 30, 2025	SEC EDGAR
Annual report	10-K	Dec 31, 2024	Mar 27, 2025	SEC EDGAR
Current report	8-K	Mar 27, 2025	Mar 27, 2025	SEC EDGAR
Current report	8-K	Mar 12, 2025	Mar 18, 2025	SEC EDGAR
Current report	8-K	Jan 7, 2025	Jan 7, 2025	SEC EDGAR
Quarterly report	10-Q	Sep 30, 2024	Nov 21, 2024	SEC EDGAR
Current report	8-K	Nov 21, 2024	Nov 21, 2024	SEC EDGAR
Current report	8-K	Oct 15, 2024	Oct 15, 2024	SEC EDGAR

Where these numbers come from

Parsed from the XBRL in Camp4 Therapeutics's annual and quarterly filings with the SEC
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Against peers

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is CAMP.

Compare: CAMP vs PRAX · CAMP vs XENE · CAMP vs TRDA · CAMP vs ACRS · CAMP vs COYA

Revenue growth39.9% · median -76.4%

Operating margin-1001.1% · median -1414.0%

Net margin-2276.3% · median -1244.1%

Company	Revenue	Growth
ACRS	$6.40M	-59.3%
CAMP	$5.32M	+39.9%
COYA	$4.69M	+17.6%
TRDA	$3.98M	-93.5%
PRAX	–	–
XENE	$0	-100.0%

Company

Exchange: Nasdaq
Industry: Pharmaceutical Preparations
Fiscal year ends: December 31
Employees: 48
Held by institutions: 66.5%
Auditor: Ernst & Young LLP
SEC CIK: 1736730

Advertisement
300 × 250

See a number that looks wrong?